What is Synbio Technologies?
Synbio Technologies operates at the intersection of biotechnology and industrial manufacturing, providing a comprehensive suite of services that includes gene synthesis, protein expression, and advanced gene editing. The company distinguishes itself through a one-stop service model that caters to the rigorous demands of global researchers. By integrating AI-enhanced protein production technologies with high-precision manufacturing standards, Synbio Technologies addresses the growing need for cost-effective, scalable solutions in molecular diagnostics and recombinant collagen production. Their platform serves as a foundational pillar for scientific breakthroughs, enabling laboratories to outsource complex genetic engineering tasks to a specialized, high-throughput provider.
How much funding has Synbio Technologies raised?
Synbio Technologies has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Synbio Technologies
PPP
Public-Private Partnership
What's next for Synbio Technologies?
With the successful closure of this late-stage financing, Synbio Technologies is poised to transition into a phase of aggressive operational expansion. The strategic allocation of this capital will likely focus on enhancing their proprietary AI-driven production pipelines and expanding their global footprint to meet the rising demand for synthetic biology services. As the industry shifts toward more complex, custom-engineered biological products, the company's ability to maintain high-quality standards while scaling output will be the primary driver of its long-term competitive advantage. Future growth will likely involve deepening their portfolio in oligonucleotide diagnostics and exploring new frontiers in recombinant protein manufacturing to maintain their leadership in the synthetic biology sector.
See full Synbio Technologies company page
